Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists provides symptomatic relief but do not prevent its progression. Thus, additional approaches aimed at slowing the progression of the disease have been investigated. Reports detailing reduced brain glucose metabolism in the early stages of AD led to the hypothesis that alternate energy sources aimed at increasing neuronal metabolism may protect neurons and thus benefit patients with AD. Medium-chain triglycerides (MCTs) are metabolized to ketone bodies that serve as an alternative source of energy for neurons. Data from clinical trials suggest that MCTs improve cognition in patients with mild to moderate AD in apolipoprotein E4–negative patients. Adverse events observed were mild and included minor gastrointestinal problems such as diarrhea, dyspepsia, and flatulence. However, since genomic profiles are not routinely conducted in patients with AD in a clinical setting, the role of MCTs in clinical practice seems to be minimal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“Neuronal metabolism is a novel and an attractive target to treat AD since reports suggest that brain glucose metabolism is reduced in early stages of AD.(9,10) Reduced glucose concentration may adversely affect the hippocampus that is responsible for consolidation of memory.”
BackgroundThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
Van der Auwera, I., Wera, S., Van Leuven, F., & Henderson, S. T. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-28 · Cited by 307
Craft, S., Dagogo-Jack, S. E., Wiethop, B. V., Murphy, C., Nevins, R. T., Fleischman, S., Rice, V., Newcomer, J. W., & Cryer, P. E. (1993) · Behavioral Neuroscience · doi:10.1037/0735-7044.107.6.926 · Cited by 191
Magnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease
Mosconi, L., De Santi, S., Rusinek, H., Convit, A., & de Leon, M. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.831 · Cited by 46 · cited 1×
“Neuronal metabolism is a novel and an attractive target to treat AD since reports suggest that brain glucose metabolism is reduced in early stages of AD.(9,10) Reduced glucose concentration may adversely affect the hippocampus that is responsible for consolidation of memory.”
Background
Cited by
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference
Morley, J. E., Morris, J. C., Berg-Weger, M., Borson, S., Carpenter, B. D., del Campo, N., Dubois, B., Fargo, K., Fitten, L. J., Flaherty, J. H., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.06.017 · Cited by 328
Ketogenic diets and Alzheimer’s disease
Lange, K. W., Lange, K. M., Makulska-Gertruda, E., Nakamura, Y., Reissmann, A., Kanaya, S., & Hauser, J. (2017) · Food Science and Human Wellness · doi:10.1016/j.fshw.2016.10.003 · Cited by 56
Hu, L.-T., Zhu, B.-L., Lai, Y.-J., Long, Y., Zha, J.-S., Hu, X.-T., Zhang, J. H., & Chen, G.-J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.069 · Cited by 35
Metadata
- Authors
- Sharma, A., Bemis, M., & Desilets, A. R.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2014-01-09
- Volume
- 29
- Issue
- 5
- Pages
- 409-414
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2008291093
- Cited by
- 52
- References
- 9
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer’s Disease. https://app.cochat.ai/papers/10.1177/1533317513518650
- The paper
- Sharma, A., Bemis, M., & Desilets, A. R. (2014). Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer’s Disease. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317513518650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.